Enanta Pharmaceuticals | ENTA - Interest Expense On Debt


Enanta Pharmaceuticals reported $1.96M in Interest Expense on Debt for its fiscal quarter ending in December of 2024.





Interest Expense On Debt Change Date
AbbVie USD 645M 69M Mar/2026
Amgen USD 95.64B 94.98B Jun/2026
Anika Therapeutics 183.47M 4.09M Jun/2026
Arrowhead Research USD 24.56M 716K Jun/2026
AstraZeneca USD 340M 144M Jun/2026
BioCryst Pharmaceuticals USD 21.71M 7.58M Jun/2026
Biogen USD 72.6M 12.6M Jun/2025
Bristol-Myers Squibb USD 407M 4M Jun/2026
Enanta Pharmaceuticals USD 1.96M 620K Dec/2024
Gilead Sciences USD 247M 7M Jun/2026
GlaxoSmithKline GBP 121M 46M Jun/2026
Halozyme Therapeutics USD 5.59M 80K Jun/2026
Heron Therapeutics USD 600K 100K Dec/2024
Immunic 197K 222K Dec/2025
Incyte USD 582K 13K Jun/2026
Insmed USD 18.84M 1.24M Jun/2026
Ionis Pharmaceuticals USD 18M 1000K Jun/2026
J&J USD 43M 25M Mar/2026
Karyopharm Therapeutics USD 12.55M 66K Mar/2026
Ligand Pharmaceuticals USD 1.78M 875K Dec/2025
Merck USD 525M 46M Jun/2026
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Novartis USD 462M 119M Jun/2026
Novavax USD 5.82M 342K Dec/2025
Pfizer USD 667M 4M Jun/2026
PTC Therapeutics USD 3.25B 381.37M Jun/2026
Roche Holding CHF 304M 7.5M Jun/2025
Sarepta Therapeutics USD 21.51M 205K Jun/2026
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025